GlobeNewswire
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
📊
AI Sentiment
Positive
7/10
- Home
- RLMD
as of 12-08-2025 3:46pm EST
$4.12
$0.12
-2.83%
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Chart Type:
Time Range:
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 307.3M | IPO Year: | N/A |
| Target Price: | $5.50 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.24 - $5.12 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered RLMD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 78.62%
78.62%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Relmada Therapeutics Inc. (RLMD)
Kelly Paul Edward
Buy
Chief Operating Officer
RLMD Nov 5, 2025
Avg Cost/Share
$2.20
Shares
90,000
Total Value
$198,000.00
Owned After
502,295
SEC Form 4
TRAVERSA SERGIO
Buy
Chief Executive Officer
RLMD Nov 5, 2025
Avg Cost/Share
$2.20
Shares
272,500
Total Value
$599,500.00
Owned After
1,272,500
SEC Form 4
Ence Chuck
Buy
CAO and COO
RLMD Nov 5, 2025
Avg Cost/Share
$2.20
Shares
136,000
Total Value
$299,200.00
Owned After
403,931
SEC Form 4
Shenouda Maged
Buy
Chief Financial Officer
RLMD Nov 5, 2025
Avg Cost/Share
$2.20
Shares
500,000
Total Value
$1,100,000.00
Owned After
788,335
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Kelly Paul Edward | RLMD | Chief Operating Officer | Nov 5, 2025 | Buy | $2.20 | 90,000 | $198,000.00 | 502,295 | |
| TRAVERSA SERGIO | RLMD | Chief Executive Officer | Nov 5, 2025 | Buy | $2.20 | 272,500 | $599,500.00 | 1,272,500 | |
| Ence Chuck | RLMD | CAO and COO | Nov 5, 2025 | Buy | $2.20 | 136,000 | $299,200.00 | 403,931 | |
| Shenouda Maged | RLMD | Chief Financial Officer | Nov 5, 2025 | Buy | $2.20 | 500,000 | $1,100,000.00 | 788,335 |
Latest Relmada Therapeutics Inc. News
RLMD Breaking Stock News: Dive into RLMD Ticker-Specific Updates for Smart Investing
Compare RLMD vs Leading Stocks
See how RLMD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RLMD Relmada Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.